Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
SB

Szofia Bullain

Vice President, Alzheimer's clinical development, Biogen

Appears in 1 story

Notable Quotes

The tau reduction was unprecedented, letting us target another core pathology of the disease.

Stories

Biogen's tau drug slows Alzheimer's decline in first-of-its-kind trial

New Capabilities

Leading diranersen's move to late-stage trials

For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.

Updated 1 hour ago